Research ArticleCancer

Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases

See allHide authors and affiliations

Science Translational Medicine  21 Mar 2018:
Vol. 10, Issue 433, eaar1916
DOI: 10.1126/scitranslmed.aar1916

Think globally, act locally in cancer

Immunotherapy for cancer is becoming increasingly common, but systemic immunotherapy can have major side effects because it stimulates the activity of the entire immune system and is not necessarily tumor-specific. Surgery, a classic mainstay of cancer treatment, has the drawback of temporarily suppressing the immune response at the site of tumor resection. To address both of these concerns, Park et al. designed hydrogel scaffolds that can gradually release agonists of innate immunity and then implanted these scaffolds into mouse models at the sites of tumor resection. This approach was safe and more effective than systemic or even local injection of immunotherapy, suggesting its potential for clinical testing.

View Full Text

Stay Connected to Science Translational Medicine